Pharmacokinetic and antiretroviral activity in mice of oral [P 1,P 2-bis[2-(adenin-9-yl)ethoxymethyl]phosphate], a prodrug of 9-(2-phosphonylmethoxyethyl)adenine

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 3, 2002, Pages 365-374

  Rossi, Luigia ^a   Dominici, Sabrina ^a   Serafini, Sonja ^a   Casabianca, Anna ^a   Cerasi, Aurora ^a   Chiarantini, Laura ^a   Celeste, Angela Gabriela ^a   Cappellacci, Loredana ^b   Franchetti, Palmarisa ^b   Grifantini, Mario ^b   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; P1,P2 BIS[2 (ADENIN 9 YL)ETHOXYMETHYL]PHOSPHONATE; PRODRUG; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; EPSTEIN BARR VIRUS; FEMALE; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HYPERGAMMAGLOBULINEMIA; LONG TERM CARE; LYMPHADENOPATHY; NONHUMAN; PHARMACOKINETICS; RETROVIRUS; VIRUS INFECTION;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BLOOD CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DNA, VIRAL; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; PRODRUGS; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; TUMOR CELLS, CULTURED;

EID: 0036735236     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Broad-spectrum anti-DNA virus and antiretrovirus activity of phosphonylmethoxyalkylpurines and pyrimidines
2. Marked in vivo antiretrovirus 9-(2-phosphonylmethoxyethyl)adenine, a selective anti human immunodeficiency virus agent
3. 9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replications in vitro and simian immunodeficiency virus infection in rhesus monkeys
4. Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,2-diaminopurine (PMEADAP) in the prophylaxis of retrovirus infection in vivo
5. 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections
6. Antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered
7. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo
8. Cellular uptake of phosphonylmethoxyalkylpurine derivatives
9. Antiretroviral activity and pharmacokinetics in mice of oral Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the Bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine
10. Determination of 9-(2-phosphonylmethoxy)ethyl]adenine in rat urine by high-performance liquid chromatography with fluorescence detection
11. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl)adenine in cynomolgus monkeys
12. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients
13. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the anti-viral agent 9-[(2-phosphonylmethoxy)ethyl]adenine (PMEA)
14. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxyl(9-[2-bis(pivaloyloxymethyl)phosphonylmethoxyethyl]adenine in HIV-infected patients
15. Adefovir dipivoxyl (bis-POM PMEA) treatment for chronic hepatitis B infection: A placebo-controlled Phase I/II study
16. Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus
17. Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds
18. Functional T lymphocytes are required for a murine retrovirus induced immunodeficiency (MAIDS)
19. Inhibition of murine AIDS by reduced glutathione
20. New treatment protocol including lympholytic and antiretroviral drugs to inhibit murine AIDS
21. Role of macrophage protection in the development of murine AIDS
22. Inhibition of murine AIDS by combination of AZT and dideoxycytidine-5′-triphosphate
23. Metabolism, mitochondrial uptake and toxicity of 2′,3′-dideoxycytidine
24. Efficacy and toxicity of long-term administration of 2′,3′-dideoxycytidine in the LP-BM5 murine-induced immunodeficiency model
25. Murine acquired immunodeficiency syndrome (MAIDS): An animal model to study the AIDS pathogenesis
26. 3′Azido-3′-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia virus, a possible animal model for antiretroviral drug screening
27. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion
28. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: A randomized, placebo-controlled trial
29. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion trasporter 1
30. Retrovirus-induced murine acquired immunodeficiency syndrome: Natural history of infection and differing susceptibility of inbred mouse strains
31. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS
32. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine